How does givinostat actually slow down muscle weakness in Duchenne muscular dystrophy?
Givinostat blocks an enzyme called histone deacetylase, which allows dormant genes to turn on and produce proteins that protect muscle cells from breaking down. In the EPIDYS trial, boys taking givinostat lost walking ability 35% more slowly than those on placebo over 18 months [1].
In Duchenne muscular dystrophy, the gene that makes dystrophin protein is broken, so muscles gradually weaken and stop working. Givinostat works by blocking histone deacetylase, an enzyme that normally keeps certain protective genes turned off. When this enzyme is blocked, those genes wake up and produce proteins that help muscle cells survive longer, even without dystrophin [1][3].
Think of histone deacetylase as a lock on a filing cabinet full of muscle-protection blueprints. Givinostat is the key that opens that lock, letting your body read and use those blueprints to build extra defenses inside muscle cells. This happens at the molecular level inside every cell that takes the medication [3][4].
The real-world benefit is measurable: boys in the EPIDYS trial who took givinostat kept their ability to walk and climb stairs for several extra months compared to placebo. However, givinostat does not cure Duchenne muscular dystrophy or restore the broken dystrophin gene—it simply slows the decline, giving families more time [1][2].
Ask your child's neurologist: 'Has my son had genetic testing to confirm the dystrophin mutation?' This confirms the diagnosis and ensures givinostat is the right fit. Genetic counseling can also help you understand inheritance patterns and options for future pregnancies.